L. Morgan

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

William M. Lee, M. Colombo, R. Talwani, 2017, Hepatology.

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

R. Dagan, M. Haranaka, A. Pedley, 2021, Vaccine.

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

S. Madhi, K. Feemster, R. Dagan, 2023 .

A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV.

S. Madhi, K. Feemster, R. Dagan, 2023, AIDS (London).

C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders

William M. Lee, M. Colombo, R. Talwani, 2016 .